Inflammation: Canakinumab for the cryopyrin-associated periodic syndromes

Nature Reviews Rheumatology

Volumn 5, Issue 10, 2009, Pages 529-530

  Savic, Sinisa ^a   McDermott, Michael F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; CRYOPYRIN; ILARIS; INTERLEUKIN 1; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; UNCLASSIFIED DRUG;

ARTICLE; AUTOINFLAMMATORY DISEASE; BIOLOGICAL THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE MUTATION; HUMAN; IMMUNOPATHOGENESIS; INJECTION SITE REACTION; MUCKLE WELLS SYNDROME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1BETA;

EID: 70349966204     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.195     Document Type: Article

References (7)

1. Mathews, R. J., Sprakes, M. & McDermott, M. F. Nod-like receptors and inflammation. Arthritis Res. Ther. 10, 228 (2008).
2. Agostini, L. et al. NALP3 forms an Il-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 30, 319-325 (2004).
3. Mansky-Goldbach, R. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355, 581-592 (2006).
4. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425 (2009).
5. Lachmann, H. J. et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206, 1029-1036 (2009).
6. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452 (2008).
7. Ruperto, N. et al. A phase II trial with canakinumab (ACZ885), A new IL-1β blocking monoclonal antibody to evaluate the safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis [abstract OP-0298]. Arthritis Rheum. 68 (Suppl. 3), 170-171 (2009).